Henshaw Capital’s Bristol-Myers Squibb BMY Stock Holding History

Henshaw Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5,930	Closed	-$422K	–	257
2022 Q3	$422K	Hold	5,930	–	–	0.03%	159
2022 Q2	$457K	Buy	+5,930	New	+$452K	0.03%	155

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Henshaw Capital's BMY Position: Q4 2022 in Review

Henshaw Capital sold out of Bristol-Myers Squibb (BMY) in Q4 2022, closing a stake of 5,930 shares — an estimated $422K sold.

Henshaw Capital first reported a position in BMY in Q2 2022 and held it in 2 quarters. The position peaked at $457K in Q2 2022. 2,602 funds tracked by Wall St. Rank hold BMY as of Q4 2022.

Henshaw Capital reported no remaining Bristol-Myers Squibb position as of Q4 2022 after selling out during the quarter.
Henshaw Capital sold 5,930 Bristol-Myers Squibb shares in Q4 2022, an estimated $422K.
Henshaw Capital first reported a position in Bristol-Myers Squibb in Q2 2022 and held it in 2 quarters.
Henshaw Capital's Bristol-Myers Squibb position peaked at $457K in Q2 2022.
2,602 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2022.

Based on Henshaw Capital's 13F filing for Q4 2022, filed 28 May 2026.